Evolus Inc.(EOLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EOLS Evolus Inc.

Market Closed 12-12 16:00:00 EST

7.04

+0.13

+1.88%

盘后6.95

-0.09-1.28%

19:16 EST

High7.05	Low6.84	Vol644.81K
Open6.90	D1 Closing6.91	Amplitude3.04%
Mkt Cap456.33M	Tradable Cap356.22M	Total Shares64.82M
T/O4.49M	T/O Rate1.27%	Tradable Shares50.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EOLS","market":"US","secType":"STK","nameCN":"Evolus Inc.","latestPrice":7.04,"timestamp":1765573200000,"preClose":6.91,"halted":0,"volume":644809,"hourTrading":{"tag":"盘后","latestPrice":6.95,"preClose":7.04,"latestTime":"19:16 EST","volume":15147,"amount":106604.68,"timestamp":1765584992274},"delay":0,"floatShares":50598952,"shares":64819784,"eps":-0.913772,"marketStatus":"Market Closed","change":0.13,"latestTime":"12-12 16:00:00 EST","open":6.9,"high":7.05,"low":6.84,"amount":4493834.0270747,"amplitude":0.030391,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.913772,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1518066000000,"exchange":"NASDAQ","adjPreClose":6.91,"preHourTrading":{"tag":"盘前","latestPrice":7.04,"preClose":6.91,"latestTime":"08:03 EST","volume":115,"amount":807.479975,"timestamp":1765544621625},"postHourTrading":{"tag":"盘后","latestPrice":6.95,"preClose":7.04,"latestTime":"19:16 EST","volume":15147,"amount":106604.68,"timestamp":1765584992274},"volumeRatio":0.6490433001205109,"impliedVol":0.8472,"impliedVolPercentile":0.732},"requestUrl":"/m/hq/s/EOLS","defaultTab":"news","newsList":[{"id":"2588708783","title":"U.S. RESEARCH ROUNDUP- Green Brick Partners, Pultegroup, Toll Brothers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708783","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708783?lang=en_us&edition=fundamental","pubTime":"2025-12-02 15:06","pubTimestamp":1764659172,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Green Brick Partners, Pultegroup, Toll BrothersDec 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL8N3X8089:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRBK","LU2112291526.USD","BK4096","IQV","KBH","ULTA","MRP","LU0079474960.USD","DE","MDB","LU1057294990.SGD","LU2211817866.USD","LU1064131342.USD","LU1868837300.USD","LU2108987350.USD","LU0345770308.USD","LU0980610538.SGD","BV","EOLS","BK4123","DFH","LEN","DHI","FWONA","LU0211331839.USD","IE0004445239.USD","LU0882574139.USD","ROK","CELC","CRL","SDHC","LU0757428866.USD","EPR","LU0823417737.USD","LU2211815571.USD","FWONK","NVR","TKO","LU1988902786.USD","LU0432979614.USD","LU0456855351.SGD","CF","FTRE","ICFI","ACAD","LU1917777945.USD","PHM","BK4120","TOL"],"gpt_icon":1},{"id":"2588089419","title":"Evolus Inc : Mizuho Cuts Target Price to $19 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2588089419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588089419?lang=en_us&edition=fundamental","pubTime":"2025-12-02 13:01","pubTimestamp":1764651712,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X70WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EOLS"],"gpt_icon":0},{"id":"2583773681","title":"BRIEF-Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583773681","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583773681?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:06","pubTimestamp":1763154419,"startTime":"0","endTime":"0","summary":"BRIEF-Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Nov 14 (Reuters) - Evolus Inc EOLS.O:EVOLUS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw1JzX5maFurther company coverage: EOLS.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUAYSLTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2581938050","title":"Evolus (EOLS) Receives a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2581938050","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581938050?lang=en_us&edition=fundamental","pubTime":"2025-11-06 17:36","pubTimestamp":1762421763,"startTime":"0","endTime":"0","summary":"In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Evolus, with a price target of $20.00. According to TipRanks, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evolus-eols-receives-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evolus-eols-receives-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","EOLS","BK4207","MFG"],"gpt_icon":0},{"id":"2581050669","title":"Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Conmed (CNMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581050669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581050669?lang=en_us&edition=fundamental","pubTime":"2025-11-06 17:31","pubTimestamp":1762421480,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Evolus (EOLS – Research Report) and Conmed (CNMD – Research Repor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evolus-eols-and-conmed-cnmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evolus-eols-and-conmed-cnmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LU0029874061.USD","LU0757428866.USD","LABU","XLV","BK4007","LU0053671581.USD","BK4588","LU1878469433.USD","BK4581","HCSG","BK4137","LU0128526141.USD","LU1815336091.USD","EOLS","BK4585","CNMD","XBI"],"gpt_icon":0},{"id":"2581052130","title":"Evolus Inc : Mizuho Raises Target Price to $20 From $19","url":"https://stock-news.laohu8.com/highlight/detail?id=2581052130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581052130?lang=en_us&edition=fundamental","pubTime":"2025-11-06 17:03","pubTimestamp":1762419821,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI0V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2581070177","title":"Evolus Inc. Unveils Investor Presentation Highlighting Jeuveau and Evolysse Market Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2581070177","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581070177?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:44","pubTimestamp":1762379086,"startTime":"0","endTime":"0","summary":"Evolus Inc. has released a new investor presentation detailing updates on its product portfolio, including Jeuveau, its botulinum toxin product, and the Evolysse line of hyaluronic acid  gels. The presentation outlines recent developments in business strategy, market positioning, product adoption, and ongoing clinical and regulatory programs. Evolus also discusses key factors affecting the market, such as competition, consumer trends, and economic conditions. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL136GCy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2581707474","title":"Evolus sees FY25 revenue $295M-$305M, consensus $296.03M","url":"https://stock-news.laohu8.com/highlight/detail?id=2581707474","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581707474?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:33","pubTimestamp":1762378404,"startTime":"0","endTime":"0","summary":"Evolus (EOLS) Reaffirms: Total net revenues for the full-year 2025 to be between $295 million and $305 million, representing 11% to 15% growth over...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evolus-sees-fy25-revenue-295m-305m-consensus-296-03m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evolus-sees-fy25-revenue-295m-305m-consensus-296-03m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2581702642","title":"Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702642","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702642?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:23","pubTimestamp":1762377805,"startTime":"0","endTime":"0","summary":"Evolus Inc. has reaffirmed its 2025 net revenue guidance, projecting total net revenue between $295 million and $305 million for the year. The company also maintains its forecast for non-GAAP operating expenses in the range of $208 million to $213 million. In the third quarter of 2025, Evolus reported total net revenue of $69.0 million, representing a 13% increase compared to the same period in 2024 and a year-to-date growth of 10%. Notably, global Jeuveau net revenue reached $63.2 million in Q3 2025, up from $59.7 million in Q2 2025, showing sequential growth that surpassed typical seasonal trends. Additionally, the launch of Evolysse generated $5.7 million in revenue, marking the strongest debut for a hyaluronic acid filler in over a decade. The company now expects to achieve positive non-GAAP operating income of $5 million to $7 million in the fourth quarter of 2025 and remains on track to achieve sustainable annual profitability beginning in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL6xQ9wD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2581701439","title":"Evolus Reports Double-Digit Revenue Growth and Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2581701439","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581701439?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:09","pubTimestamp":1762376944,"startTime":"0","endTime":"0","summary":"Evolus Inc. reported its financial results for the third quarter ended September 30, 2025, highlighting double-digit growth despite current market conditions. The company posted total net revenue of $69.0 million, with $63.2 million attributed to global Jeuveau sales, reflecting sequential growth that exceeded typical seasonal trends. In the U.S., Evolus achieved a year-to-date market share of 14%. The company also generated $5.7 million in revenue from Evolysse, noting this as the most successful hyaluronic acid  filler launch in over a decade. Strategic expense reductions implemented mid-year lowered operating costs and strengthened the financial position in the second half of the year. Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and projected non-GAAP operating expenses of $208 million to $213 million. The company expects to achieve profitability in the fourth quarter and sustainable annual profitability beginning in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL8D4XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2577369076","title":"Evolus Inc. to Announce Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2577369076","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577369076?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:01","pubTimestamp":1761134467,"startTime":"0","endTime":"0","summary":"Evolus Inc. will report its third quarter 2025 financial results on November 5, 2025, after the U.S. financial markets close. Results will be released on the Investor Relations page of the Evolus website. A conference call and live webcast with Evolus management will be held at 4:30 p.m. ET on the same day, accessible via the Investor Relations page of the Evolus website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire  on October 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL3DvDFt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2574787102","title":"Evolus Announces New Inducement Stock Options and RSUs for Newly Hired Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2574787102","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574787102?lang=en_us&edition=fundamental","pubTime":"2025-10-11 04:05","pubTimestamp":1760126717,"startTime":"0","endTime":"0","summary":"Evolus Inc. has granted non-qualified stock options to purchase a total of 24,931 shares and 31,116 restricted stock units  to nine newly hired non-executive employees. The stock options have an exercise price of $6.26 per share, with a 10-year term, and both the options and RSUs vest over four years, with 25% vesting on each annual anniversary of the October 7, 2025 vesting commencement date. Recipients must remain continuously employed on each vesting date to receive the awards.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire  on October 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL5HV80z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EOLS"],"gpt_icon":0},{"id":"2574176277","title":"Leerink Partners Keeps Their Buy Rating on Evolus (EOLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2574176277","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574176277?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:25","pubTimestamp":1760099120,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Marc Goodman maintained a Buy rating on Evolus on October 7. The company’s shares closed yesterday at $6.23. According to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-evolus-eols-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-evolus-eols-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EOLS"],"gpt_icon":0},{"id":"2574941041","title":"Evolus Inc. Files Initial Statement of Beneficial Ownership for Chief Financial Officer Tatjana Mitchell","url":"https://stock-news.laohu8.com/highlight/detail?id=2574941041","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574941041?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:57","pubTimestamp":1760043479,"startTime":"0","endTime":"0","summary":"Evolus Inc. has filed an initial statement of beneficial ownership with the SEC. The filing lists Tatjana Mitchell as the beneficial owner, serving as Chief Financial Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL4RvT96:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2567141656","title":"Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2567141656","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567141656?lang=en_us&edition=fundamental","pubTime":"2025-09-16 02:27","pubTimestamp":1757960878,"startTime":"0","endTime":"0","summary":"Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements. Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&D and launched its first two products, Hemotese and CollapatII. The presentation also notes a strengthened R&D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.Disclaimer: This news brief was ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL5tFvH1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EOLS"],"gpt_icon":0},{"id":"2567590203","title":"BRIEF-Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2567590203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567590203?lang=en_us&edition=fundamental","pubTime":"2025-09-13 05:41","pubTimestamp":1757713265,"startTime":"0","endTime":"0","summary":"BRIEF-Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Sept 12 (Reuters) - Evolus Inc EOLS.O:EVOLUS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw8py7m0aFurther company coverage: EOLS.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nTUA7JCQW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EOLS"],"gpt_icon":0},{"id":"2567902409","title":"Evolus Inc. Announces New Inducement Grants for Employees Under 2023 Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2567902409","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567902409?lang=en_us&edition=fundamental","pubTime":"2025-09-13 05:30","pubTimestamp":1757712612,"startTime":"0","endTime":"0","summary":"Evolus Inc., a performance beauty company, has announced new compensation terms for its recent hires, including the new Chief Financial Officer, Tatjana Mitchell. The company has granted non-qualified stock options and restricted stock units  as part of its 2023 Inducement Incentive Plan. Six newly hired non-executive employees have received options to purchase a total of 8,744 shares of common stock, with an exercise price of $7.66 per share, and 15,000 RSUs. Tatjana Mitchell has been awarded options for 143,403 shares at an exercise price of $7.61 per share and 104,603 RSUs. Both stock options and RSUs follow a vesting schedule over four years, with non-executive employee options and RSUs vesting 25% annually. Mitchell's RSUs vest 50% on the third anniversary and 50% on the fourth anniversary of the vesting commencement date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL2Gnyyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2566885633","title":"Evolus Price Target Maintained With a $18.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2566885633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566885633?lang=en_us&edition=fundamental","pubTime":"2025-09-08 23:58","pubTimestamp":1757347080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EOLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 08, 2025 11:58 ET (15:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EOLS"],"gpt_icon":0},{"id":"2565684507","title":"Evolus Names Tatjana Mitchell CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2565684507","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565684507?lang=en_us&edition=fundamental","pubTime":"2025-09-08 21:01","pubTimestamp":1757336503,"startTime":"0","endTime":"0","summary":"Evolus (EOLS) said Monday it has named Tatjana Mitchell its chief financial officer.Mitchell succeeds Sandra Beaver, who left the company in June.Mitchell was previously Experian's senior vice president of corporate finance, Evolus said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EOLS","BK4007"],"gpt_icon":0},{"id":"2565681662","title":"Evolus Inc. Appoints Tatjana Mitchell as Chief Financial Officer to Drive Growth and Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2565681662","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565681662?lang=en_us&edition=fundamental","pubTime":"2025-09-08 20:30","pubTimestamp":1757334641,"startTime":"0","endTime":"0","summary":"Evolus, Inc. has appointed Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Mitchell brings over 20 years of finance leadership experience, having previously held senior roles at Experian and Zulily. Her appointment is expected to support Evolus's growth in the performance beauty sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire  on September 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDLc05qgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EOLS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evolus.com","stockEarnings":[{"period":"1week","weight":0.0277},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0209},{"period":"6month","weight":-0.291},{"period":"1year","weight":-0.3921},{"period":"ytd","weight":-0.3623}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.317178},{"month":2,"riseRate":0.714286,"avgChangeRate":0.223908},{"month":3,"riseRate":0.25,"avgChangeRate":-0.114517},{"month":4,"riseRate":0.375,"avgChangeRate":-0.079842},{"month":5,"riseRate":0.75,"avgChangeRate":0.314215},{"month":6,"riseRate":0.625,"avgChangeRate":0.011271},{"month":7,"riseRate":0.5,"avgChangeRate":-0.007335},{"month":8,"riseRate":0.375,"avgChangeRate":0.042226},{"month":9,"riseRate":0.25,"avgChangeRate":-0.131057},{"month":10,"riseRate":0.625,"avgChangeRate":-0.053423},{"month":11,"riseRate":0.5,"avgChangeRate":-0.016865},{"month":12,"riseRate":0.375,"avgChangeRate":-0.039981}],"exchange":"NASDAQ","name":"Evolus Inc.","nameEN":"Evolus Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evolus Inc.(EOLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Evolus Inc.(EOLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Evolus Inc.,EOLS,Evolus Inc.股票,Evolus Inc.股票老虎,Evolus Inc.股票老虎国际,Evolus Inc.行情,Evolus Inc.股票行情,Evolus Inc.股价,Evolus Inc.股市,Evolus Inc.股票价格,Evolus Inc.股票交易,Evolus Inc.股票购买,Evolus Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evolus Inc.(EOLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Evolus Inc.(EOLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction